(Q47918020)

6 February 2018

title

Nebulised dornase alpha: adherence in adults with cystic fibrosis (English)

1 reference

6 February 2018

0 references

Judith A Burrows

1

1 reference

6 February 2018

Julie P Bunting

series ordinal

2

1 reference

6 February 2018

Philip J Masel

series ordinal

3

1 reference

6 February 2018

Scott C Bell

series ordinal

4

1 reference

6 February 2018

publication date

1 December 2002

1 reference

6 February 2018

Journal of Cystic Fibrosis

published in

1 reference

6 February 2018

volume

1

1 reference

6 February 2018

issue

4

1 reference

6 February 2018

page(s)

255-259

1 reference

6 February 2018

The role of mucous glycoproteins in the rheologic properties of cystic fibrosis sputum

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900095-4

7 January 2021

In vivo effects of recombinant human DNase I on sputum in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900095-4

7 January 2021

Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900095-4

7 January 2021

A preliminary study of aerosolized recombinant human deoxyribonuclease I in the treatment of cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900095-4

7 January 2021

Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900095-4

7 January 2021

Efficacy and safety of short-term administration of aerosolised recombinant human DNase I in adults with stable stage cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900095-4

7 January 2021

Two years experience with recombinant human DNase I in the treatment of pulmonary disease in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900095-4

7 January 2021

Retrospective review of the effects of rhDNase in children with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900095-4

7 January 2021

Long-term effects of aerosolised rhDNase on pulmonary disease progression in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900095-4

7 January 2021

Compliance with treatment in adult patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900095-4

7 January 2021

Treatment compliance in adults with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900095-4

7 January 2021

Is This Patient Taking the Treatment as Prescribed?

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900095-4

7 January 2021

Determinants of adherence in adults with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900095-4

7 January 2021

10.1016/S1569-1993(02)00095-4

Identifiers

DOI

1 reference

6 February 2018

release_dsih5soyxfa4nn6jlwosxnxpky

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/dsih5soyxfa4nn6jlwosxnxpky

24 November 2022

mapped directly with Wikidata item

1 reference

6 February 2018